Iovance Biotherapeutics, Inc.
IOVA
$6.98
$0.467.06%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 40.14% | -9.93% | 21.20% | 18.27% | 3.88% |
| Total Depreciation and Amortization | -0.12% | -17.63% | 8.28% | -4.50% | 11.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 26.12% | -32.51% | 48.70% | -59.26% | 21.34% |
| Change in Net Operating Assets | -178.13% | -76.66% | 14.53% | -195.93% | 150.85% |
| Cash from Operations | 15.59% | -37.11% | 33.21% | -16.69% | 34.96% |
| Capital Expenditure | 17.66% | 29.10% | 14.05% | -45.34% | -20.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -481.12% | 78.33% | -63.76% | 30.76% | -3.51% |
| Cash from Investing | -749.90% | 1,370.19% | -95.44% | 22.90% | -12.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -48.78% | 74.00% | -36.04% | 544.55% | -90.78% |
| Repurchase of Common Stock | 72.10% | -839.10% | 4.51% | 7.54% | 91.07% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -47.75% | 67.94% | -36.21% | 565.58% | -90.77% |
| Foreign Exchange rate Adjustments | 41.78% | -136.92% | 184.85% | -192.02% | 45.47% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -356.35% | 574.37% | -80.69% | 164.80% | -170.78% |